Shorter-acting psychedelics for therapy; the Cancer Moonshot needs economists; and much more

March 19, 2023 Check out STAT+

Sponsored By

By Torie Bosch Editor, First Opinion

This week in First Opinion: Psychedelic therapies need a lot of changes — including shorter-acting drugs — to reach their potential; the Cancer Moonshot has to keep affordability in mind; AI chatbots for health require a human touch; and more. Please keep reading and sending ideas and essays to first.opinion@statnews.com. For more on what I'm looking for in First Opinion pieces, see this Twitter thread.

COLE BURSTON/AFP via Getty Images The second age of psychedelic therapies for mental health It will take some doing to make psychedelic therapies that use psilocybin and ketamine ready for prime time. By Greg Mayes The Cancer Moonshot will never take off without economists and finance experts Cancer Moonshot advances in science must be accompanied by progress in controlling costs and innovations in financing cancer treatment. By Jeff Levin-Scherz NRC: be straight about when clinicians need to report errors that lead to radiation exposure Each year, medical error results in radiation exposure that exceeds reporting levels for roughly 28,000 people in the U.S. By Daniel Fass and David Townsend Adobe STAT+ | AI chatbots can improve health — but only with help from humans When it comes to providing people with accurate information, chatbots in health care need help from humans. By Smisha Agarwal and Rose Weeks The staggering financial burden of a proposed HIPAA rule The HIPAA Privacy Rule change would upend the model for releasing patients' medical information to third-party requestors. By Angie Comfort STAT+ | Drug developers navigating 'biology's century' need a model. We made one Biopharma R&D productivity has been in steady decline for at least three decades. Reversing this trend will require many interventions. By Brian Finrow and Aleks Engel and Srinivas Akkaraju Listen: Big changes for First Opinion On the "First Opinion Podcast," retiring editor Pat Skerrett chats with Torie Bosch, who's just joined STAT as our new First Opinion editor. By Patrick Skerrett and Torie Bosch

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying First Opinion? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser